Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade

Leukemia. 2014 Apr;28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20.

¹ 1] Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria [2] Department of Cell Biology, University of Salzburg, Salzburg, Austria.
² Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria.
³ Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, Munich, Germany.
⁴ Department of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria.
⁵ Division of Experimental Dermatology and EB House Austria, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria.
⁶ Department of Pathology, Paracelsus Medical University, Salzburg, Austria.
⁷ Department of Cell Biology, University of Salzburg, Salzburg, Austria.

No abstract available

Publication types

Antigens, CD19 / analysis
Cell Proliferation / drug effects*
Clotrimazole / pharmacology
Humans
Intermediate-Conductance Calcium-Activated Potassium Channels / antagonists & inhibitors*
Intermediate-Conductance Calcium-Activated Potassium Channels / physiology
Ki-67 Antigen / analysis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
Potassium Channel Blockers / pharmacology*
Pyrazoles / pharmacology